Division of Biological Sciences, University of California San Diego, La Jolla, California, United States of America.
PLoS One. 2021 Nov 18;16(11):e0257089. doi: 10.1371/journal.pone.0257089. eCollection 2021.
Recombinant production of viral proteins can be used to produce vaccine antigens or reagents to identify antibodies in patient serum. Minimally, these proteins must be correctly folded and have appropriate post-translation modifications. Here we report the production of the SARS-CoV-2 spike protein Receptor Binding Domain (RBD) in the green algae Chlamydomonas. RBD fused to a fluorescent reporter protein accumulates as an intact protein when targeted for ER-Golgi retention or secreted from the cell, while a chloroplast localized version is truncated. The ER-retained RBD fusion protein was able to bind the human ACE2 receptor, the host target of SARS-CoV-2, and was specifically out-competed by mammalian cell-produced recombinant RBD, suggesting that the algae produced proteins are sufficiently post-translationally modified to act as authentic SARS-CoV-2 antigens. Because algae can be grown at large scale very inexpensively, this recombinant protein may be a low cost alternative to other expression platforms.
病毒蛋白的重组生产可用于生产疫苗抗原或用于鉴定患者血清中抗体的试剂。这些蛋白质至少必须正确折叠并具有适当的翻译后修饰。在这里,我们报告了在绿藻衣藻中生产 SARS-CoV-2 刺突蛋白受体结合域(RBD)。当靶向 ER-Golgi 保留或从细胞中分泌时,与荧光报告蛋白融合的 RBD 作为完整的蛋白质积累,而定位于叶绿体的版本则被截断。ER 保留的 RBD 融合蛋白能够结合人类 ACE2 受体,即 SARS-CoV-2 的宿主靶标,并被哺乳动物细胞产生的重组 RBD 特异性竞争,表明藻类产生的蛋白具有足够的翻译后修饰,可作为真正的 SARS-CoV-2 抗原。由于藻类可以非常廉价地大规模生长,因此这种重组蛋白可能是其他表达平台的低成本替代物。